Drug Landscape ›
CYPROHEPTADINE HYDROCHLORIDE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 814
Most-reported reactions
Vomiting — 95 reports (11.67%) Fatigue — 87 reports (10.69%) Off Label Use — 87 reports (10.69%) Diarrhoea — 86 reports (10.57%) Pneumonia — 84 reports (10.32%) Rash — 83 reports (10.2%) Headache — 79 reports (9.71%) Product Dose Omission Issue — 73 reports (8.97%) Pruritus — 71 reports (8.72%) Anxiety — 69 reports (8.48%)
Source database →
CYPROHEPTADINE HYDROCHLORIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is CYPROHEPTADINE HYDROCHLORIDE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for CYPROHEPTADINE HYDROCHLORIDE in United States?
Marketing authorisation holder not available in our data.